olivLaw · US equity research
Axcelis Technologies, Inc. ACLS
Special Industry Machinery, NEC · SIC 3559 · Vertical: Special Industry Machinery, NEC (SIC 3559)
Axcelis Technologies designs and manufactures ion implantation equipment used in making semiconductor chips, supported by a substantial aftermarket service and spare parts business. The company reported lower revenue in 2025, but revenue returned to growth in the second quarter of 2026 and management expects revenue growth for the full year 2026 while the Veeco merger is still pending.
At the close of 30 Oct 2026, Axcelis Technologies, Inc. (ACLS) stock was 100.07 USD (−10.67% on the day), with market capitalisation 3.1 bn USD, P/E 33.5 on diluted EPS of 2.98 USD over the last 12 months, beta 2.01, 52-week range 74.12–191.60 USD. Latest reported quarter (Q2 2026): revenue of 215.2 m USD (+10.6% YoY), net income of 23.3 m USD (−25.8% YoY), diluted EPS 0.75 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 35.2
- weak (30–45)
- Bollinger (20, 2)
- 94.26 – 144.26
- in the lower half of the band · %B 0.12 · band width 41.9%
- SMA 50 / 200
- 118.51 / 123.13
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -4.60 / -3.22
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −23.7% | −0.9% | −22.8 pp | — |
| 3 months | −23.2% | +1.2% | −24.5 pp | — |
| 6 months | −28.5% | +4.8% | −33.4 pp | — |
| Year to date | +24.6% | +10.7% | +13.8 pp | — |
| 1 year | +22.3% | +11.1% | +11.2 pp | +23.8% |
| 3 years | −21.5% | +80.7% | −102.3 pp | +19.3% |
| 5 years | +82.2% | +64.6% | +17.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 256.6 m | 252.4 m | 192.6 m | 194.5 m | 213.6 m | 238.3 m | 199.0 m | 215.2 m |
| Cost of revenue | 146.6 m | 136.2 m | 103.8 m | 107.2 m | 124.8 m | 126.4 m | 118.4 m | 124.0 m |
| Gross profit | 110.0 m | 116.2 m | 88.8 m | 87.3 m | 88.8 m | 111.9 m | 80.6 m | 91.2 m |
| Research & development | 26.4 m | 27.7 m | 27.1 m | 27.1 m | 24.6 m | 30.1 m | 28.5 m | 29.0 m |
| Operating income | 46.9 m | 54.5 m | 29.2 m | 29.0 m | 25.0 m | 36.2 m | 8.0 m | 20.3 m |
| Depreciation & amortisation | 3.9 m | 4.3 m | 4.3 m | 4.5 m | 4.3 m | 4.5 m | 4.4 m | 4.4 m |
| Interest expense | 1.3 m | 1.4 m | 1.4 m | 1.4 m | 1.3 m | 1.3 m | 1.3 m | 1.3 m |
| Pre-tax income | 55.4 m | 58.6 m | 33.1 m | 35.0 m | 30.2 m | 40.0 m | 10.6 m | 25.3 m |
| Income tax | 6.8 m | 8.7 m | 4.5 m | 3.6 m | 4.2 m | 5.7 m | 1.4 m | 2.1 m |
| Net income | 48.6 m | 50.0 m | 28.6 m | 31.4 m | 26.0 m | 34.3 m | 9.2 m | 23.3 m |
| Diluted EPS | 1.49 | 1.54 ≈ | 0.88 | 0.98 | 0.83 | 1.10 ≈ | 0.30 | 0.75 |
| Operating cash flow | 45.7 m ≈ | 12.8 m | 39.8 m | 39.7 m ≈ | 45.4 m ≈ | -6.6 m | 18.1 m | 18.4 m ≈ |
| Capex | 3.9 m ≈ | 4.7 m | 5.0 m | 2.0 m ≈ | 2.0 m ≈ | 2.3 m | 1.8 m | 3.6 m ≈ |
| Share repurchases | 15.4 m ≈ | 15.1 m | 18.2 m | 45.3 m ≈ | 32.3 m ≈ | 25.2 m | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 90 percentile of its own 39-quarter history (min 5.1, median 20.8, max 63.5; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 442.6 m | 343.0 m | 474.6 m | 662.4 m | 920.0 m | 1.1 bn | 1.0 bn | 839.0 m |
| Revenue YoY | +7.8% | −22.5% | +38.4% | +39.6% | +38.9% | +22.9% | −10.0% | −17.6% |
| Net income | 45.9 m | 17.0 m | 50.0 m | 98.7 m | 183.1 m | 246.3 m | 201.0 m | 120.2 m |
| Net income YoY | −63.9% | −62.9% | +193.4% | +97.4% | +85.6% | +34.5% | −18.4% | −40.2% |
| Diluted EPS | 1.35 | 0.50 | 1.46 | 2.88 | 5.46 | 7.43 | 6.15 | 3.80 |
| Diluted EPS YoY | −64.5% | −63.0% | +192.0% | +97.3% | +89.6% | +36.1% | −17.2% | −38.2% |
| net % | 10.4% | 5.0% | 10.5% | 14.9% | 19.9% | 21.8% | 19.7% | 14.3% |
| Free cash flow | 42.3 m | -25.6 m | 62.3 m | 141.5 m | 204.9 m | 136.2 m | 128.6 m | 107.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 145.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 1.0 bn USD
- Total assets
- 1.4 bn USD
- Debt / equity
- unavailable
- Current ratio
- 4.77x
- ROE
- 11.7%
- ROA
- 8.9%
- FCF margin
- 12.8%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 474.6 m | 662.4 m | 920.0 m | 1.1 bn | 1.0 bn | 839.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 276.0 m | 376.0 m | 518.2 m | 639.3 m | 563.2 m | 462.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | 198.6 m | 286.4 m | 401.8 m | 491.3 m | 454.7 m | 376.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Research & development | 61.8 m | 65.4 m | 78.4 m | 96.9 m | 105.5 m | 109.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | 58.0 m | 127.3 m | 212.4 m | 265.8 m | 210.8 m | 119.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 9.9 m | 10.8 m | 11.6 m | 13.1 m | 15.8 m | 17.6 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | 68.0 m ≈ | 138.1 m ≈ | 224.0 m ≈ | 278.9 m ≈ | 226.6 m ≈ | 136.9 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 5.2 m | 4.8 m | 5.6 m | 5.3 m | 5.5 m | 5.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | 55.9 m | 120.4 m | 204.9 m | 278.6 m | 230.3 m | 138.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | 5.9 m | 21.8 m | 21.8 m | 32.3 m | 29.3 m | 18.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Net income | 50.0 m | 98.7 m | 183.1 m | 246.3 m | 201.0 m | 120.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | 1.46 | 2.88 | 5.46 | 7.43 | 6.15 | 3.80 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 34.1 m | 34.3 m | 33.5 m | 33.2 m | 32.7 m | 31.7 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 203.5 m | 294.9 m | 185.6 m | 167.3 m | 123.5 m | 145.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 86.9 m | 104.4 m | 169.8 m | 218.0 m | 203.1 m | 168.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | 161.1 m | 195.0 m | 242.4 m | 306.5 m | 282.2 m | 329.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 470.8 m | 619.2 m | 877.6 m | 1.1 bn | 1.1 bn | 943.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 29.8 m | 35.0 m | 39.7 m | 54.0 m | 53.8 m | 56.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 624.6 m | 753.2 m | 1.0 bn | 1.3 bn | 1.3 bn | 1.4 bn | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 24.0 m | 38.0 m | 62.3 m | 54.4 m | 46.9 m | 42.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 84.4 m | 150.1 m | 248.1 m | 285.1 m | 207.5 m | 197.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 143.0 m | 214.3 m | 346.4 m | 417.1 m | 336.0 m | 326.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 481.6 m † | 539.0 m † | 667.3 m † | 864.9 m † | 1.0 bn † | 1.0 bn † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 69.7 m | 150.2 m | 215.6 m | 156.9 m | 140.8 m | 118.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 7.4 m | 8.7 m | 10.7 m | 20.7 m | 12.2 m | 11.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | 62.3 m ≈ | 141.5 m ≈ | 204.9 m ≈ | 136.2 m ≈ | 128.6 m ≈ | 107.0 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -7.3 m | -8.7 m | -257.3 m | -100.9 m | -108.7 m | 29.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | -2.4 m | -52.5 m | -65.5 m | -68.3 m | -71.2 m | -124.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Share repurchases | 7.5 m | 50.0 m | 57.5 m | 52.5 m | 60.5 m | 121.1 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
Score: 41 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
30 Oct 2026Source: olivLaw, closing series
Market cap: 3.1 bn USD
Key indicators
Coverage and freshness
Score by group
- Returns27
- Quality54
- Growth0
- Valuation40
- Balance sheet100
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 53.50 – 110.33 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E53.50 – 110.33 (Mid 75.39)7 companies used · median multiple 25.3x · quartiles 17.9x – 37.0xACMR, ASYS, CRCT, CVV, ERII, LRCX, SOTK
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 41/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 10.7% | 50 (vs peers) | 10% |
| FCF conversion · Quality | 70.6% | 58 (on a fixed band) | 10% |
| Revenue CAGR 3Y · Growth | -3.0% | 0 (on a fixed band) | 13% |
| EPS CAGR 3Y · Growth | -11.4% | 0 (on a fixed band) | 13% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 17.2x | 100 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 4.9x | 100 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | 33.5x | 50 (vs peers) | 16% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 2.1% | 27 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | 1.9% | 27 (on a fixed band) | 10% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality54/100 · 2/3 factors with a value
- Returns· partial27/100 · 1/2 factors with a value
- Valuation40/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
AXCELIS TECHNOLOGIES INC (ACLS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 839.0 m USD in 2025; YoY growth -17.6%; net margin 10.7%; ROE 8.9%.
The estimated value range is 53.50–110.33 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 75.39 USD, the price of 100.07 USD leaves a potential of -24.7% (value / price − 1) and a margin of safety of -32.7% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 41/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Interest coverage: 17.2x
- Current ratio: 4.9x
What contradicts it
- Revenue CAGR 3Y: -3.0%
- EPS CAGR 3Y: -11.4%
- FCF yield: 2.1%
- Shareholder yield (distributions): 1.9%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net debt / EBITDA, EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Special Industry Machinery, NEC (SIC 3559) · same industry (4-digit SIC) · compared with 12 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LRCXLam Research Corporation | 298.7 bn | 35.6 | 70.1% | 32.3% | +26.0% | +52% / +306% |
| ACLSAxcelis Technologies Inc | 3.1 bn | 33.5 | 8.9% | 10.7% | −17.6% | +22% / −22% |
| VECOVeeco Instruments Inc | 2.4 bn | 108.5 | 2.6% | 3.4% | −7.4% | +35% / +62% |
| AZTAAzenta, Inc. | 1.7 bn | — | -7.7% | -20.0% | +3.6% | +29% / −14% |
| CRCTCricut, Inc. | 1.3 bn | 14.3 | 25.9% | 12.7% | −0.5% | +15% / −29% |
| ACMRACM Research, Inc. | 644.6 m | 21.5 | 10.6% | 14.5% | +15.2% | +10% / +234% |
| ERIIEnergy Recovery, Inc. | 355.3 m | 25.3 | 8.6% | 12.7% | −6.9% | −59% / −54% |
| ASYSAmtech Systems, Inc. | 223.2 m | 48.2 | 4.8% | 4.9% | −21.6% | +61% / +78% |
| VELOVelo3D, Inc. | 210.9 m | — | -61.5% | -89.6% | +12.1% | +18% / −99% |
| SOTKSono Tek Corp | 75.8 m | 38.4 | 10.1% | 9.3% | +2.0% | +6% / −4% |
| TRTTrio-Tech International | 50.6 m | — | -0.1% | -0.1% | +71.6% | +32% / +43% |
| CVVCvd Equipment Corporation | 27.2 m | 2.7 | 32.7% | 62.0% | −4.1% | +0% / −32% |
| ASMLAsml Holding NV | — | — | 50.5% | 29.4% | +15.6% | +48% / +162% |
1- and 3-year price returns: for ACLS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 55.07 Total return -45% · Per year -45% | 97.74 Total return -2% · Per year -2% | 147.75 Total return 48% · Per year 48% |
| 3 years | 45.67 Total return -54% · Per year -23% | 91.92 Total return -8% · Per year -3% | 153.65 Total return 54% · Per year 15% |
| 5 years | 37.87 Total return -62% · Per year -18% | 86.45 Total return -14% · Per year -3% | 159.78 Total return 60% · Per year 10% |
- Exit P/E± 22.98
- Net margin± 16.09
- Annual revenue growth± 14.23
- Annual dilution± 1.35
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Axcelis Technologies designs and manufactures ion implantation equipment used in making semiconductor chips, supported by a substantial aftermarket service and spare parts business. The company reported lower revenue in 2025, but revenue returned to growth in the second quarter of 2026 and management expects revenue growth for the full year 2026 while the Veeco merger is still pending.
SWOT
Strengths
- A focused implant portfolio with a recognized Purion product line and a strong position in power devices 1.
- The aftermarket division brings recurring revenue and a growing share of sales, which can steady results when equipment investment slows 1.
- Second-quarter 2026 results beat the company's forecasts, and the company holds considerable liquid assets 3.
Weaknesses
Opportunities
Risks
- Dependence on chipmaker capital spendinghigh
If investment in capacity falls, demand for Axcelis systems could drop quickly, and the fixed cost structure could reduce profitability 1.
- Customer concentrationhigh
The ten largest customers generate a dominant share of revenue, and the absence of long-term purchase agreements makes revenue vulnerable 12.
- Export restrictions on Chinahigh
U.S. controls could limit shipments to Chinese customers, who represent a significant share of sales, and the policies could change 1.
- Tariff and supply chain riskmedium
Tariff policies are volatile and could raise component costs if the limited group of suppliers increases prices 1.
- Veeco merger completion riskmedium
The transaction depends on regulatory approvals, including from China, and a failure or delay could affect strategic plans 2.
Investment thesis
What would need to be true (bull case)
- Second-quarter revenue growth and positive expectations for the third quarter could indicate a return of demand in memory and power segments 3.
- The aftermarket division keeps growing and offers a steadier revenue base than system sales 1.
- If the Veeco merger closes, the company could broaden its offerings and reduce dependence on a single product category 2.
What would break the thesis
- Annual revenue for 2025 fell from the prior year, and net income dropped below 2024 levels 1.
- Customer concentration and dependence on China remain major risks if export restrictions tighten 12.
- The Veeco merger could bring complex integration and extra costs if approvals are delayed or terms change 2.
What to watch
- Revenue delivery against the roughly 230 million USD outlookQ3 2026
- Completion of the Veeco merger and approval from Chinese authoritiessecond half of 2026
- Changes to export controls affecting Chinese customersnext 10-K
- System sales trends in the general mature and memory segments2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Axcelis designs, manufactures and services ion implantation systems, a key step in forming transistors in semiconductor chips 1. Over 98% of 2025 revenue came from ion implantation, with the rest from aftermarket sales tied to legacy systems 1. The company also provides lifecycle services through its Customer Solutions & Innovation division, covering spare parts, upgrades, maintenance and training 1.
In September 2025 Axcelis agreed to merge with Veeco Instruments, under which Veeco would become a wholly-owned subsidiary 2. Completion depends on customary closing conditions, including final approval from China's regulator, and the companies expect the deal to close in the second half of 2026 2.
Segments
Trends
- Demand for memory and power chipstailwind
Management reported robust demand in the memory segment and positive momentum in power, which could support shipment volumes if the trend continues 3.
- Recovery in general mature segmenttailwind
Customer engagement in the general mature segment appears to be improving as end demand in data centers, industrial and automotive grows, which could support fab utilization 3.
- Export controls and trade policyheadwind
U.S. restrictions on exports to China and uncertainty over tariffs could limit sales to an important customer group and raise costs 1.
- Shifts in the investment cyclemixed
Service activity could be steadier than system sales, but customers who maintain their own equipment can reduce aftermarket revenue, so the overall effect is mixed 1.
Competitive position
The ion implant segment is highly competitive, with one much larger competitor that has greater financial and engineering resources and several smaller companies offering innovative technology 1. Non-U.S. suppliers such as Nissin, Sumitomo Heavy Industries and Advanced Ion Beam Technology are cited as alternatives for Chinese customers 1.
Price competition and margin pressure can affect profitability, especially if new products do not meet market demand on time 1. Chinese companies developing implanters for the domestic market pose a further longer-term threat 1.
- Larger competitor in ion implantation
The filing describes one competitor with substantially greater financial and engineering resources, without naming it.
- Nissin Ion Equipment
Non-U.S. ion implanter supplier cited as an alternative for Chinese customers.
- Sumitomo Heavy Industries Ion Technology
Japanese ion implanter supplier cited as an alternative for Chinese customers.
- Advanced Ion Beam Technology
Supplier that could win orders from Chinese customers if relationships with Axcelis change.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report27 Oct 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report08 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Current report06 May 2026Shareholder vote
- Proxy statement31 Mar 2026
- Current report12 Mar 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Annual report26 Feb 2026
- Current report17 Feb 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Axcelis Technologies, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Axcelis Technologies, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Axcelis Technologies, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.